Molecular Subtype
HER2-Positive Breast Carcinoma
CI-CAN-00007795Explore in graph →
140 active trials3 approved drugs93 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007795Explore in graph →
Variants & evidence
117 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| PIK3CA Mutation1 | |||||||
| Trastuzumab Emtansine | Predictive | B | Does Not Support Resistance | 3 | accepted | EID8536In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA Overexpression4 | |||||||
| Dactolisib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8269In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) monotherapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PIK3CA amplification. Auth… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8268In a preclinical study, efficacy of lapatinib monotherapy was evaluated in vitro against HER2 amplified breast cancer cell lines (BT474 and SKBR3) with retrovirally induced PIK3CA expression. Authors … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib + TrastuzumabCombination | Predictive | D | Supports Sensitivity Response | 2 | accepted | ||
| PTEN Expression1 | |||||||
| Everolimus + FulvestrantCombination | Predictive | C | Supports Resistance | 1 | accepted | EID1624Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classica… (full text at CIViC) PMID 27445490 · Sun et al., 2016 · Open in CIViC | civic |
| PTEN Loss11 | |||||||
| Dactolisib + Lapatinib + TrastuzumabCombination | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8280In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induc… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Everolimus | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1297Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC) PMID 27091708 · André et al., 2016 · Open in CIViC | civic |
| PI-103 | Predictive | D | Supports Sensitivity Response | 1 | accepted | ||
Data updated 18 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
In a preclinical study, efficacy of lapatinib and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell lines (BT474 and SKBR3) with retrovirally induced PIK… (full text at CIViC)
PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC
| civic |
| Trastuzumab | Predictive | D | Supports Resistance | 2 | accepted | EID8267HER2-positive breast cancer cell lines (BT-474 and SKBR3) were retrovirally transduced with wildtype PIK3CA and treated with trastuzumab. PIK3CA overexpression diminished the growth inhibitory effects… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC)
PMID 20453058 · O'Brien et al., 2010 · Open in CIViC
| civic |
| PI3Ka/Di | Predictive | D | Supports Resistance | 1 | accepted | EID8022As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Pictilisib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID2045This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | Predictive | B | Supports Resistance | 3 | accepted | EID1385A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC | civic |
| 〃 | Predictive | B | Does Not Support Resistance | 3 | accepted | EID1386While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second o… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Resistance | 2 | accepted | EID2035In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured … (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID1383A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in… (full text at CIViC) PMID 17936563 · Berns et al., 2007 · Open in CIViC | civic |
| Trastuzumab Emtansine | Predictive | B | Does Not Support Resistance | 3 | accepted | EID8706In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ad… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PI3K/BET Inhibitor LY294002 + TrastuzumabCombination | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1455Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition,… (full text at CIViC) PMID 15324695 · Nagata et al., 2004 · Open in CIViC | civic |